Müller-Quernheim, Joachim 1953-
Joachim Müller-Quernheim
VIAF ID: 176146707141200792029 ( Personal )
Permalink: http://viaf.org/viaf/176146707141200792029
Preferred Forms
4xx's: Alternate Name Forms (1)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Analysis of single nucleotide polymorphisms in chronic beryllium disease | |
Association study for 26 candidate loci in idiopathic pulmonary fibrosis patients from four european populations | |
Bedeutung des Scavengerrezeptors Klasse A Typ I (CD204) als Kollagenrezeptor der Alveolarmakrophagen | |
CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential | |
CD90 - ein Marker der Transdifferenzierung von Makrophagen | |
Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis | |
Erratum for Maler et al., "Key Role of the Scavenger Receptor MARCO in Mediating Adenovirus Infection and Subsequent Innate Responses of Macrophages" | |
FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients | |
Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes | |
Genetic and geographic influence on phenotypic variation in European sarcoidosis patients | |
High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls | |
Impact of lung function decline on mortality in lung transplant recipients: long-term results from the L-CsA-i study for the prevention of bronchiolitis obliterans syndrome | |
impact of pulmonary function in patients undergoing autologous stem cell transplantation | |
Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome | |
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial | |
Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis | |
Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? | |
Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis | |
Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis | |
Prevention of M2 polarization and temporal limitation of differentiation in monocytes by extracellular ATP | |
Pro-fibrotic effects of CCL18 on human lung fibroblasts are mediated via CCR6 | |
Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis | |
Pulmonary granulomatosis of genetic origin | |
A randomized trial of everolimus‐based quadruple therapy vs standard triple therapy early after lung transplantation | |
Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II | |
Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial | |
Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas | |
Sex differences in the genetics of sarcoidosis across European and African ancestry populations | |
Überblick über 10 Jahre Lungentransplantation an der Uniklinik Freiburg und der Stellenwert der bronchoalveolären Lavage (BAL) für die Nachsorge : eine klinische Studie an 110 Patienten nach Lungentransplantation | |
value of bronchoalveolar lavage for discrimination between healthy and diseased individuals |